ILLUMINATE_SKIN_CLINICS_L - Accounts

Company Registration No. 09039008 (England and Wales)
ILLUMINATE SKIN CLINICS LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2023
ILLUMINATE SKIN CLINICS LTD
COMPANY INFORMATION
Director
Dr S M Shotter
Company number
09039008
Registered office
35 Kings Hill Avenue
Kings Hill
KENT
ME19 4DG
Accountants
William Duncan + Co Ltd
44 Bank Street
Kilmarnock
Ayrshire
United Kingdom
KA1 1HA
ILLUMINATE SKIN CLINICS LTD
CONTENTS
Page
Accountants' report
1
Balance sheet
2 - 3
Notes to the financial statements
4 - 10
ILLUMINATE SKIN CLINICS LTD
REPORT TO THE DIRECTOR ON THE PREPARATION OF THE UNAUDITED STATUTORY ACCOUNTS OF ILLUMINATE SKIN CLINICS LTD
- 1 -

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Illuminate Skin Clinics Ltd for the year ended 31 August 2023 which comprise, the balance sheet and the related notes from the company’s accounting records and from information and explanations you have given us.

 

As a practising member firm of the ICAS we are subject to its ethical and other professional requirements which are detailed at https://icas.com/icas-framework-preparation-of-accounts.

This report is made solely to the Board of Directors of Illuminate Skin Clinics Ltd, as a body, in accordance with the terms of our engagement letter. Our work has been undertaken solely to prepare for your approval the financial statements of Illuminate Skin Clinics Ltd and state those matters that we have agreed to state to the Board of Directors of Illuminate Skin Clinics Ltd, as a body, in this report in accordance with the requirements of the ICAS as detailed at https://icas.com/icas-framework-preparation-of-accounts. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Illuminate Skin Clinics Ltd and its Board of Directors as a body, for our work or for this report.

It is your duty to ensure that Illuminate Skin Clinics Ltd has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and loss of Illuminate Skin Clinics Ltd. You consider that Illuminate Skin Clinics Ltd is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of Illuminate Skin Clinics Ltd. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.

William Duncan + Co Ltd
24 May 2024
Chartered Accountants
44 Bank Street
Kilmarnock
Ayrshire
United Kingdom
KA1 1HA
ILLUMINATE SKIN CLINICS LTD
BALANCE SHEET
AS AT 31 AUGUST 2023
31 August 2023
- 2 -
2023
2022
Notes
£
£
£
£
Fixed assets
Tangible assets
4
490,491
589,812
Current assets
Stocks
64,348
69,944
Debtors
5
173,977
124,690
Cash at bank and in hand
67,614
297,773
305,939
492,407
Creditors: amounts falling due within one year
6
(589,068)
(533,158)
Net current liabilities
(283,129)
(40,751)
Total assets less current liabilities
207,362
549,061
Creditors: amounts falling due after more than one year
7
(338,270)
(351,158)
Provisions for liabilities
(60,547)
(54,408)
Net (liabilities)/assets
(191,455)
143,495
Capital and reserves
Called up share capital
8
104
104
Share premium account
99,974
99,974
Capital redemption reserve
26
26
Profit and loss reserves
(291,559)
43,391
Total equity
(191,455)
143,495

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 31 August 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The director acknowledges her responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

ILLUMINATE SKIN CLINICS LTD
BALANCE SHEET (CONTINUED)
AS AT 31 AUGUST 2023
31 August 2023
- 3 -
The financial statements were approved and signed by the director and authorised for issue on 24 May 2024
Dr S M Shotter
Director
Company registration number 09039008 (England and Wales)
ILLUMINATE SKIN CLINICS LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2023
- 4 -
1
Accounting policies
Company information

Illuminate Skin Clinics Ltd is a private company limited by shares incorporated in England and Wales. The registered office is 35 Kings Hill Avenue, Kings Hill, KENT, ME19 4DG.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

Atruet the time of approving the financial statements, the director has a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the director continues to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

 

Turnover relates to medical aesthetic services.

1.4
Intangible fixed assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Software
33.3% on cost

The asset has been fully amortised.

1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Leasehold improvements
20% on cost
Plant and equipment
20% on cost
Fixtures and fittings
25% on cost
Computers
33.3% on cost
ILLUMINATE SKIN CLINICS LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2023
1
Accounting policies
(Continued)
- 5 -

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.6
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

 

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

1.7
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.8
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

ILLUMINATE SKIN CLINICS LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2023
1
Accounting policies
(Continued)
- 6 -
1.9
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

1.10
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.11
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

1.12
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.13
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

ILLUMINATE SKIN CLINICS LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2023
1
Accounting policies
(Continued)
- 7 -
1.14
Leases

Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessees. All other leases are classified as operating leases.

 

Assets held under finance leases are recognised as assets at the lower of the assets fair value at the date of inception and the present value of the minimum lease payments. The related liability is included in the balance sheet as a finance lease obligation. Lease payments are treated as consisting of capital and interest elements. The interest is charged to profit or loss so as to produce a constant periodic rate of interest on the remaining balance of the liability.

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2023
2022
Number
Number
Total
13
10
3
Intangible fixed assets
Other
£
Cost
At 1 September 2022 and 31 August 2023
14,767
Amortisation and impairment
At 1 September 2022 and 31 August 2023
14,767
Carrying amount
At 31 August 2023
-
0
At 31 August 2022
-
0
ILLUMINATE SKIN CLINICS LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2023
- 8 -
4
Tangible fixed assets
Land and buildings
Plant and machinery etc
Total
£
£
£
Cost
At 1 September 2022
429,238
419,847
849,085
Additions
3,865
63,025
66,890
At 31 August 2023
433,103
482,872
915,975
Depreciation and impairment
At 1 September 2022
31,928
227,345
259,273
Depreciation charged in the year
86,597
79,614
166,211
At 31 August 2023
118,525
306,959
425,484
Carrying amount
At 31 August 2023
314,578
175,913
490,491
At 31 August 2022
397,310
192,502
589,812
5
Debtors
2023
2022
Amounts falling due within one year:
£
£
Trade debtors
13,399
10,503
Other debtors
98,862
52,471
112,261
62,974
2023
2022
Amounts falling due after more than one year:
£
£
Other debtors
61,716
61,716
Total debtors
173,977
124,690
ILLUMINATE SKIN CLINICS LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2023
- 9 -
6
Creditors: amounts falling due within one year
2023
2022
£
£
Bank loans and overdrafts
6,591
6,687
Trade creditors
163,136
98,549
Amounts owed to group undertakings
311,328
311,328
Taxation and social security
10,882
7,332
Other creditors
97,131
109,262
589,068
533,158
7
Creditors: amounts falling due after more than one year
2023
2022
£
£
Bank loans and overdrafts
32,460
38,674
Other creditors
305,810
312,484
338,270
351,158
8
Called up share capital
2023
2022
2023
2022
Ordinary share capital
Number
Number
£
£
Issued and fully paid
A Ordinary shares of £1 each
104
104
104
104
9
Operating lease commitments
Lessee

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

2023
2022
£
£
113,226
82,415
10
Related party transactions
Transactions with related parties

During the year the company entered into the following transactions with related parties:

ILLUMINATE SKIN CLINICS LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2023
10
Related party transactions
(Continued)
- 10 -

The company recharged expenses totalling £64,277 to Balance Medical Ltd, a company with a common director and shareholder. As at 31 August 2023 the balance outstanding was £4,276 (31.8.22 - £6,176), which is included in Debtors.

 

The company recharged expenses totalling £37,022 to Sophie Mariette Consulting Ltd, 100% shareholder. As at 31 August 2023 the balance outstanding was £65, which is included in Debtors.

 

The company was charged £120,000 for services from Sophie Mariette Consulting Ltd. As at 31 August 2023 the balance outstanding was £10,000, which is included in Creditors

 

There is a balance due to be paid to Sophie Mariette Consulting Ltd totalling £311,328.

 

 

2023-08-312022-09-01false24 May 2024CCH SoftwareCCH Accounts Production 2024.100No description of principal activityDr S M Shotterfalsefalse090390082022-09-012023-08-3109039008bus:Director12022-09-012023-08-3109039008bus:RegisteredOffice2022-09-012023-08-31090390082023-08-31090390082022-08-3109039008core:LandBuildings2023-08-3109039008core:OtherPropertyPlantEquipment2023-08-3109039008core:LandBuildings2022-08-3109039008core:OtherPropertyPlantEquipment2022-08-3109039008core:CurrentFinancialInstrumentscore:WithinOneYear2023-08-3109039008core:CurrentFinancialInstrumentscore:WithinOneYear2022-08-3109039008core:Non-currentFinancialInstrumentscore:AfterOneYear2023-08-3109039008core:Non-currentFinancialInstrumentscore:AfterOneYear2022-08-3109039008core:CurrentFinancialInstruments2023-08-3109039008core:CurrentFinancialInstruments2022-08-3109039008core:Non-currentFinancialInstruments2023-08-3109039008core:Non-currentFinancialInstruments2022-08-3109039008core:ShareCapital2023-08-3109039008core:ShareCapital2022-08-3109039008core:SharePremium2023-08-3109039008core:SharePremium2022-08-3109039008core:CapitalRedemptionReserve2023-08-3109039008core:CapitalRedemptionReserve2022-08-3109039008core:RetainedEarningsAccumulatedLosses2023-08-3109039008core:RetainedEarningsAccumulatedLosses2022-08-3109039008core:IntangibleAssetsOtherThanGoodwill2022-09-012023-08-3109039008core:ComputerSoftware2022-09-012023-08-3109039008core:LeaseholdImprovements2022-09-012023-08-3109039008core:PlantMachinery2022-09-012023-08-3109039008core:FurnitureFittings2022-09-012023-08-3109039008core:ComputerEquipment2022-09-012023-08-31090390082021-09-012022-08-3109039008core:IntangibleAssetsOtherThanGoodwill2022-08-3109039008core:IntangibleAssetsOtherThanGoodwill2023-08-3109039008core:IntangibleAssetsOtherThanGoodwill2022-08-3109039008core:LandBuildings2022-08-3109039008core:OtherPropertyPlantEquipment2022-08-31090390082022-08-3109039008core:LandBuildings2022-09-012023-08-3109039008core:OtherPropertyPlantEquipment2022-09-012023-08-3109039008core:WithinOneYear2023-08-3109039008core:WithinOneYear2022-08-3109039008core:AfterOneYear2023-08-3109039008core:AfterOneYear2022-08-3109039008bus:PrivateLimitedCompanyLtd2022-09-012023-08-3109039008bus:SmallCompaniesRegimeForAccounts2022-09-012023-08-3109039008bus:FRS1022022-09-012023-08-3109039008bus:AuditExemptWithAccountantsReport2022-09-012023-08-3109039008bus:FullAccounts2022-09-012023-08-31xbrli:purexbrli:sharesiso4217:GBP